## **Exhibit D**

# QUESTIONNAIRE FOR FILING PROPOSED RULES AND REGULATIONS WITH THE ARKANSAS LEGISLATIVE COUNCIL AND JOINT INTERIM COMMITTEE

DEPARTMENT/AGENCY_	Department of	Human Ser	vices			
DIVISION	IVISION Division of Medical Services					
DIVISION DIRECTOR	Dawn Zekis, In	nterim Direc	ctor			
CONTACT PERSON	Lisa Smith					
ADDRESS	P.O. Box 1437.	, Slot S295,	, Little Ro	ck, AR 72	2203-1437	
PHONE NO. 320-6432 NAME OF PRESENTER AT	FAX N Γ COMMITTE		2480	E- MAIL	lisa.smi	th.dms@arkansas.gov
MEETING Marilyn Strickland						
PRESENTER E-MAIL ma				<del></del>		
	;	INSTRUC	TIONS			
Arkansas Legi	ndexing your rathis questionnates osed rule and the Rules Review islative Researces fall, 5th Floor	rules, pleas aire and fin required d v Section	e give the	proposed	citation a	ifter "Short Title of ched to the front of
********	*****	*****	******	******	*****	*****
1. What is the short title of th rule?		an Amendr	nent #201	4-006		
2. What is the subject of the prule?	proposed a	Rate increas and also exp Levongestre	anding co	verage to	include the	releasing Mirena IUD e 13.5 mg
3. Is this rule required to com	ply with a feder	ral statute, r	ule, or reg	gulation?	Yes 🗌	No 🔀
If yes, please provide the fe	e federal rule, regulation, and/or statute citation.					
4. Was this rule filed under the Procedure Act? If yes, what is the effective rule?			f the Admi		Yes 🗌	No 🖂
When does the emergency expire?	rule					

	Will this emergency rule be promulgated under the permanent provisions of the Administrative Procedure Act?	Yes 🗌	No 🗌
5.	Is this a new rule? Yes No No If yes, please provide a brief summary explaining the regulation.		
	Does this repeal an existing rule? Yes \( \subseteq \text{No \text{\subseteq}} \) If yes, a copy of the repealed rule is to be included with your completed replaced with a new rule, please provide a summary of the rule giving an does. \( \frac{1}{2} \)	questionnaire. explanation o	If it is being f what the rule
rul	Is this an amendment to an existing e? Yes No  If yes, please attach a mark-up showing the changes in the existing rule a changes. Note: The summary should explain what the amendment of should be clearly labeled "mark-up."	and a summary loes, and the r	of the substantive nark-up copy
6.	Cite the state law that grants the authority for this proposed rule? If codif Code citation. <u>Arkansas Statute 20-76-201</u>	ied, please giv	e the Arkansas
rei	What is the purpose of this proposed rule? Why is it necessary? To prove the provider's cost of Mirena and the expansion of course the beneficiary access to services.	ide equitable a overage to incl	nd <u>fair</u> ude Skyla to
8.	Please provide the address where this rule is publicly accessible in electrorequired by Arkansas Code § 25-19-108(b).		

		·		
		·		
	•			
•				
	•			
		•		
			•	

#### FINANCIAL IMPACT STATEMENT

### PLEASE ANSWER ALL QUESTIONS COMPLETELY

DEPARTMENT		TMENT	Department of	Human Services					
DI	VISIC	ON	Division of Mo	edical Services					
PE	RSO	N COMPLE	ETING THIS S	TATEMENT Ly	nn Burton				
TE	LEPI	HONE NO.	501-682-1857	_ <b>FAX NO.</b> <u>3889</u>	EMAIL: lyni	n.burton@dh	s.arkansas.gov		
					se complete the followind proposed rules.	ng Financial	Impact		
SI	IORT	TITLE OF	THIS RULE	State Plan Amer	ndment #2014-006				
1.	Does	s this propos	ed, amended, or	repealed rule hav	ve a financial impact?	Yes 🛚	No 🗌		
2.	2. Is the rule based on the best reasonably obtainable scientific, technical, economic, or other evidence and information available concerning the need for, consequences of, and alternatives to the rule?  Yes   No □						No 🗌		
3.				res to this rule, wa tly rule considered	s this rule determined 1?	Yes 🔀	No 🗌		
	If an	If an agency is proposing a more costly rule, please state the following:							
	(a)	How the ad	lditional benefit	s of the more cost	ly rule justify its addition	onal cost;			
·	(b)	The reason	for adoption of	the more costly ru	ıle;				
	(c)		e more costly rue explain; and;	ale is based on the	interests of public heal	th, safety, or	welfare, and		
	(d)	Whether th explain.	e reason is with	in the scope of the	agency's statutory aut	hority; and if	so, please		
	If the	e purpose of t	his rule is to imp	olement a federal ru	lle or regulation, please s	tate the follow	wing:		
	(a)	What is the	cost to implem	ent the federal rule	e or regulation?				
	Current Fiscal Year			Next Fiscal Year					
	Fed Cas Spe	neral Revenu eral Funds h Funds cial Revenue er (Identify)	e		General Revenue Federal Funds Cash Funds Special Revenue Other (Identify)				

	Total		Total					
	(b) What is the ad	ditional cost of the state rule?	?					
	Current Fiscal Y	<u>ear</u>	Next Fiscal Year					
	General Revenue Federal Funds Cash Funds Special Revenue Other (Identify)	\$28,726 (2015) \$258,536	Federal Funds Cash Funds Special Revenue	\$38,302 (2016) \$344,714				
	Total	\$287,262	Total	\$383,016				
	What is the total es the proposed, amen explain how they an urrent Fiscal Year	timated cost by fiscal year to ded, or repealed rule? Identi e affected.	any private individual, entity fy the entity(ies) subject to the entity (ies) subject	ne proposed rule and				
6. C		stimated cost by fiscal year to e? Is this the cost of the prog		n how the government is				
\$ 28,726(2015) \$ 38,302(2016)								
Ψ 			Ψ 30,302(2010	· · · · · · · · · · · · · · · · · · ·				
7.	or obligation of at private entity, priv	e agency's answers to Questic least one hundred thousand d ate business, state government those entities combined?	lollars (\$100,000) per year to	a private individual,				
	Yes No No							
	If YES, the agency is required by Ark. Code Ann. § 25-15-204(e)(4) to file written findings at the time of filing the financial impact statement. The written findings shall be filed simultaneously with the financial impact statement and shall include, without limitation, the following:							
	(1) a statement of	the rule's basis and purpose;						
	(2) the problem the	e agency seeks to address wit ed by statute;	h the proposed rule, includin	g a statement of whether				
	(3) a description of	f the factual evidence that:						

- (a) justifies the agency's need for the proposed rule; and
- (b) describes how the benefits of the rule meet the relevant statutory objectives and justify the rule's costs:
- (4) a list of less costly alternatives to the proposed rule and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (5) a list of alternatives to the proposed rule that were suggested as a result of public comment and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (6) a statement of whether existing rules have created or contributed to the problem the agency seeks to address with the proposed rule and, if existing rules have created or contributed to the problem, an explanation of why amendment or repeal of the rule creating or contributing to the problem is not a sufficient response; and
- (7) an agency plan for review of the rule no less than every ten (10) years to determine whether, based upon the evidence, there remains a need for the rule including, without limitation, whether:
  - (a) the rule is achieving the statutory objectives;
  - (b) the benefits of the rule continue to justify its costs; and
  - (c) the rule can be amended or repealed to reduce costs while continuing to achieve the statutory objectives.

#### Summary for

SPA #2014-006 - Reimbursement Rate Increase For the 52 mg Levongestrel-Releasing Intrauterine Contraceptive System & Expansion of Coverage for the 13.5 mg Levongestrel-Releasing Intrauterine Contraceptive System

Effective for claims with dates of service occurring on and after October 1, 2014, Arkansas Medicaid will increase the Medicaid maximum reimbursement rate for the 52 mg Levongestrel-releasing Intrauterine Contraceptive System (Mirena IUD). Also effective for claims with dates of service occurring on and after October 1, 2014, Arkansas Medicaid will also expand Medicaid coverage to include the 13.5 mg Levongestrel-Releasing Intrauterine Contraceptive System (Skyla IUD). The rate is being increased and the coverage expanded in order to ensure availability of the IUD's for Arkansas Medicaid beneficiaries. Reimbursement for Mirena will be based on 100% of the manufacturer's list price as of November 18, 2013. Reimbursement for Skyla will be based on 100% of the manufacturer's listed price as of January 1, 2013. The estimated increase in annual expenditure is \$383,016.

# STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE ARKANSAS

ATTACHMENT 4.19-B Page 1v

## METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES - OTHER TYPES OF CARE

Revised:

October 1, 2014

#### 4.c. Family Planning Services

Reimbursement is based on the lesser of the amount billed or the maximum Title XIX (Medicaid) charge allowed. State developed fee schedule rates are the same for both public and private providers.

1. The Title XIX (Medicaid) maximum for Family Planning services is 100% of the current physician Medicaid maximum.

At the beginning of each calendar year, the State Agency will negotiate with the affected provider group representatives to arrive at a mutually acceptable increase or decrease from the maximum rate. Market forces, such as private insurance rate, medical and general inflation figures, changes in practice costs and changes in program requirements, will be considered during the negotiation process. Any agreed upon increase or decrease will be implemented at the beginning of the following State Fiscal Year, July 1, with any appropriate State Plan changes.

2. Intrauterine Devices (IUDs)

Effective for claims with dates of service January 1, 2014 and after, the intrauterine device (IUD) is reimbursed based on 100% of the manufacturer's list price as of April 15, 2011. Effective for claims with dates of service October 1, 2014 and after, the 52 mg Levongestrel-Releasing Intrauterine Contraceptive System is reimbursed based on 100% of the manufacturer's list price as of November 18, 2013. Effective for claims with dates of service October 1, 2014 and after, the 13.5 mg Levongestrel-Releasing Intrauterine Contraceptive System is reimbursed based on 100% of the manufacturer's list price as of January 1, 2013.



#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURI MEDICAL ASSISTANCE PROGRAM STATE ARKANSAS

**ATTACHMENT 4.19-B** Page 1v

METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES -OTHER TYPES OF CARE

Revised:

JanuaryOctober 1, 2014

Family Planning Services 4.c.

> Reimbursement is based on the lesser of the amount billed or the maximum Title XIX (Medicaid) charge allowed. State developed fee schedule rates are the same for both public and private providers.

1. The Title XIX (Medicaid) maximum for Family Planning services is 100% of the current physician Medicaid maximum.

At the beginning of each calendar year, the State Agency will negotiate with the affected provider group representatives to arrive at a mutually acceptable increase or decrease from the maximum rate. Market forces, such as private insurance rate, medical and general inflation figures, changes in practice costs and changes in program requirements, will be considered during the negotiation process. Any agreed upon increase or decrease will be implemented at the beginning of the following State Fiscal Year, July 1, with any appropriate State Plan changes.

2. Intrauterine Devices (IUDs)

> Effective for claims with dates of service January 1, 2014 and after, the intrauterine device (IUD) is reimbursed based on 100% of the manufacturer's list price as of April 15, 2011. Effective for claims with dates of service July 1, 2010October 1, 2014 and after, the 52 mg Lievongestrel-rReleasing Intrauterine Contraceptive System UD is reimbursed based on 100% of the manufacturer's list price as of May 5, 2010 November 18, 2013. Effective for claims with dates of service October 1, 2014 and after, the 13.5 mg Levongestrel-Releasing Intrauterine Contraceptive System is reimbursed based on 100% of the manufacturer's list price as of January 1, 2013.